| 摘要 |
Methods for treating bacterial infections in the colon, and colonic disorders caused by bacterial infection, using a poorly absorbable form of Rifalazil, are described. Compositions for oral administration, and colonic delivery, of a non- microgranulated Rifalazil formulation, are also described. Rifalazil is delivered in a form which is poorly absorbed in the gut after oral dosing, and the vast majority of the orally-dosed Rifalazil is not absorbed in the gut. Accordingly, the antibacterial potency in the colonic flora will be enhanced, while absorption and systemic circulation will be reduced, thus reducing potential adverse events.
|
